Skip to main content
OpenTrials
Completed

NCT Number: NCT05854095

The Study for Evaluation of Acute Phase Safety and Efficacy of 'Pivot Bridge' to Short-term Treat FTR

evaluation of safety and efficacy of 'Pivot Bridge' to short-term treat Functional Tricuspid regurgitation

Completed

Looking for future studies?

Notify Me

Key information

Age range

20 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Keimyung University Dongsan Hospital, Daegu, Dalseo-gu, South Korea

Loading trial locations.

About this study

evaluation of safety and efficacy of 'Pivot Bridge' to short-term treat Functional Tri cuspid regurgitation : multi-center, open label, single arm, investigator initiated exploratory pilo t study

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult males and females aged 20 years or above
  • Patients with clinical symptoms (Symptomatic) whose degree of tricuspid regurgitation using echocardiography meets the criteria of Severe or higher presented in the TR grade classification table
  • Short-term treatment using a catheter is required (expected to be effective) by a local site heart team including at least one cardiothoracic (cardiovascular) specialist and at least one thoracic surgeon each, and clinical symptoms of NYHA Class Ⅱ or higher person who falls under
  • In the screening test, A person who can confirm the possibility of reducing tricuspid valve regurgitation by inserting that 'Pivot Balloon' (Clinical Trial Approval No. 1327), etc.) through the same access path as the 'Pivot Bridge', a clinical trial medical device
  • An individual who voluntarily agreed to the participation in the clinical trial and signed the written consent
  • An individual who is able to understand and comply with the instructions and who can participate in the period before the clinical trial

Exclusion criteria

  • Uncontrolled hyperthyroidism
  • A recent formation of soft blood clot or embolic material
  • Uncorrected coagulopathy
  • Prohibition of anticoagulant agents
  • Those who had experience with anticoagulant use prior to participation in this clinical trial and who were treated with major bleeding (minor bleeding such as nosebleeds that can be hemostasis not applicable) due to anticoagulant use at this time or accompanied by severe anemia requiring hospitalization one with experience
  • Previous insertion of a device such as an Implantable Cardioverter Defibrillator (ICD) or a pacemaker
  • Those who is judged to have little possibility of reducing tricuspid valve regurgitation by inserting a balloon-type device (e.g. ASD sizing balloon, pivot balloon, etc.) through the same access route as the clinical trial medical device 'Pivot Bridge'
  • Persons with an anatomical structure that cannot be inserted through the corresponding route

Treatment and study plan

Pivot Bridge

Device

transcatheter for short-term treat Functional Tricuspid regurgitation

Primary outcomes

  1. Assessment of Acute phase safety

    Time frame: immediately after the procedure

    Check all adverse reactions Including serious adverse events and serious adverse medical device reactions

Secondary outcomes

  1. Efficacy endpoint-1: Changes of hemodynamics

    Time frame: within 1week of implant

    Echocardiogram: Pulmonay artery forward flow(RV stroke volume) in ml

  2. Efficacy endpoint-1: Changes of hemodynamics(1)

    Time frame: within 1week of implant

    Echocardiogram: RV Cardiac output(Heart rate x RVOT area x RVOT TVI) in ml/min

  3. Efficacy endpoint-1: Changes of hemodynamics(2)

    Time frame: within 1week of implant

    Echocardiogram: Fractional area change in percentage

  4. Efficacy endpoint-1: Changes of hemodynamics(3)

    Time frame: within 1week of implant

    Echocardiogram: LVEF in percentage

  5. Efficacy endpoint-1: Changes of hemodynamics(4)

    Time frame: within 1week of implant

    Echocardiogram: Peak systolic annular velocity in cm/sec

  6. Efficacy endpoint-1: Changes of hemodynamics(5)

    Time frame: within 1week of implant

    Echocardiogram: Tricuspid annular plane systolic excursion(TAPSE) in mm

  7. Efficacy endpoint-1: Changes of hemodynamics(6)

    Time frame: within 1week of implant

    Echocardiogram: LVOT stroke volume in ml

  8. Efficacy endpoint-1: Changes of hemodynamics(7)

    Time frame: within 1week of implant

    Echocardiogram: TV annular diameter in mm

  9. Efficacy endpoint-1: Changes of hemodynamics(8)

    Time frame: within 1week of implant

    Echocardiogram: RV diameter base in mm

  10. Efficacy endpoint-1: Changes of hemodynamics(9)

    Time frame: within 1week of implant

    Echocardiogram: Inferior vena cava diameter and PW tracing - Assessment of the presence or absence of systolic flow reversal

  11. Efficacy endpoint-1: Changes of hemodynamics(10)

    Time frame: within 1week of implant

    Echocardiogram: RV-RA coupling(Tapse/PASP) in ratio

  12. Efficacy endpoint-1: Changes of hemodynamics(11)

    Time frame: within 1week of implant

    Cardiac CT : RV volume in ml

  13. Efficacy endpoint-2: Technical feasibility and TR grade changes

    Time frame: within 1week of implant

    Evaluation of reduction in tricuspid regurgitation grade (TR grade) according to Echo parameters

  14. Assessment of short-term safety

    Time frame: within 1week of implant

    Check all adverse reactions Including serious adverse events and serious adverse medical device reactions

Sponsors and collaborators

Lead sponsor

Tau-MEDICAL Co., Ltd.

Industry

Registry information

Official study title

The Study for Evaluation of Acute Phase Safety and Efficacy of 'Pivot Bridge' to Short-term Treat Functional Tricuspid Regurgitation : Multi-center, Open Label, Single Arm, Investigator Initiated Exploratory Pilot Study

Important dates

Study start
2023
Primary completion
2023
Study completion
2023
First posted
May 11, 2023
Registry last updated
Feb 8, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.